TABLE 4.
Neutralization of BNM-III-170-treated HIV-1JR-FL by monoclonal antibodies from vaccinated monkeys and humansa
| Monoclonal antibody | gp120 epitope | IC50 (μg/ml) for: |
|||
|---|---|---|---|---|---|
| HIV-1JR-FL |
A-MLV |
||||
| Without BNM-III-170 | With BNM-III-170 | Without BNM-III-170 | With BNM-III-170 | ||
| 17b | CD4i | >30 | 0.6 ± 0.4 | >30 | >30 |
| 902090 | V2 (171–177) | >30 | 5.0 ± 2.4 | >30 | >30 |
| 830A Fab | Discontinuous V2i epitope | >10 | 0.6 | >10 | >10 |
| 900973 | C terminus (491–501) | >30 | >30 | >30 | >30 |
| 900974 | V3 (304–317) | >30 | 0.2 ± 0.0 | >30 | >30 |
| 900990 | V3 (318–327) | >30 | 5.1 | >30 | >30 |
| 902067 | V3 (304–314) | >30 | 0.2 ± 0.0 | >30 | >30 |
| GE2 JG8 | V3 (301–317) | >100 | 0.6 | >100 | >100 |
| CH22 | V3 (304–320) | >30 | 0.2 | >30 | >30 |
| CH23 | V3 (302–318) | >30 | 3.3 | >30 | 22.1 |
a
The antibody concentration (IC50) that inhibited the infection of the recombinant viruses by 50% in the absence or presence of 30 μM BNM-III-170 is reported. In this assay, the IC50s of BNM-III-170 alone were 20.7 ± 7.6 μM for HIV-1JR-FL and >100 μM for A-MLV.